Healthcare & Insurance
Interim Report Q2 2018: Continued double digit organic revenue growth drives strong EBITA margin increase. GN Audio upgrades organic growth guidance
GN Store Nord delivered 11% organic revenue growth in Q2 2018. Revenue growth was 7% including around (5)% impact from development in foreign exchange ratesEBITA margin increased 1.5 percentage points in Q2 2018 as a function of strong operational execution EPS increased 10% compared to Q2
Wednesday, August 22, 2018
Kane Biotech Announces Second Quarter 2018 Financial Results
WINNIPEG, Manitoba, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) announces its Second Quarter 2018 Financial Results. Kane Biotech Inc. is a biotechnology company engaged in the research, development and
Tuesday, August 21, 2018
Neon Therapeutics Appoints Jolie M. Siegel as General Counsel
CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the appointment of Jolie M. Siegel as general counsel, a newly created position. Ms. Siegel will lead
Tuesday, August 21, 2018
Rubius Therapeutics to Announce Second Quarter 2018 Financial Results
CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, plans to report second quarter 2018 financial results on Friday, August 31, 2018. The company will
Tuesday, August 21, 2018
Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results
Total Fourth-Quarter Revenues of $200.9 MillionFourth-Quarter Diluted EPS of $0.18 and Adjusted EPS of $0.38, Up 31 Percent SALT LAKE CITY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and
Tuesday, August 21, 2018
NeuroMetrix Receives $3.8M Milestone Payment Under Its Collaboration with GSK Consumer Healthcare
WALTHAM, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported that it had achieved the second development milestone under its strategic collaboration with GSK Consumer Healthcare. A milestone payment of $3.8 Million was made by GSK. The collaboration with
Tuesday, August 21, 2018
Ageas and BlackRock: Transparency notification
In accordance with the rules on financial transparency*, Blackrock has notified Ageas on 16 August 2018 that, on 14 August 2018, its shareholding stands at 5.14%. * article 14, paragraph 1 of the law of 2 May 2007 on disclosure of major holdings us provisions Ageas is a listed
Tuesday, August 21, 2018
Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy
EAST SETAUKET, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement with Moffitt Cancer Center to conduct a Phase 1b/2 study of the safety and therapeutic benefit of
Tuesday, August 21, 2018
NewLink Genetics to Participate in the Baird Global Healthcare Conference
AMES, Iowa, Aug. 21, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the 2018 Baird Global Healthcare Conference on Wednesday, September 5, 2018, at 11:25AM ET. A live webcast of the presentation will be available on the
Tuesday, August 21, 2018
Lexington Announces First Multicenter Clinical Study Site
Company embarks on pivotal clinical studyVANCOUVER, British Columbia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the Medical College of Wisconsin
Tuesday, August 21, 2018
Emerald Health Therapeutics Announces Appointment of Pure Sunfarms President and CEO
Mandesh Dosanjh brings extensive consumer products experience with recent cannabis focus at Liquor Control Board of Ontario VICTORIA, British Columbia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) and Village Farms International,
Tuesday, August 21, 2018
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the first patient has been enrolled under the amended protocol for its registration trial in
Tuesday, August 21, 2018
Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with
Pint Pharma to facilitate expansion of Phase 3 INSPIRE trial to Argentina, Chile, and Brazil in preparation for future studies of oral rigosertib NEWTOWN, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on
Tuesday, August 21, 2018
Progressive Care Inc. Reports 47% Increase in Prescriptions Filled During July 2018
MIAMI, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced further growth year-over-year in both revenue and number of prescriptions filled for July 2018. July brought a total of $1.887 million in net
Tuesday, August 21, 2018
GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior
Tuesday, August 21, 2018
Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab)
ROCKVILLE, Md. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a clinical trial collaboration
Tuesday, August 21, 2018
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer will present at the Rodman
Tuesday, August 21, 2018
CLS Holdings USA Names Matthew Janz as VP of Marketing and Director of Operations at Oasis Cannabis
Will Lead New Marketing Programs LAS VEGAS, Aug. 21, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiary, today
Tuesday, August 21, 2018
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment conferences: Rodman and Renshaw 20th Annual Global Investment Conference, sponsored by H.C. Wainwright
Tuesday, August 21, 2018
Biotricity Expands Salesforce to Cover Key US Markets and Begins Advisory Board Expansion to Move Into Preemptive Heart Disease Diagnostics
The Company has Expanded its Sales Team to Cover Two Additional Geographic Centers in the USREDWOOD CITY, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional
Tuesday, August 21, 2018
